Mol­e­cule-in-21-days AI start­up In­sil­i­co adds Boehringer to list of Big Phar­ma part­ners

Sev­en months af­ter their head­line-grab­bing Na­ture Biotech­nol­o­gy study and in the throes of a Covid-19 re­search ef­fort, Hong Kong-based AI start­up In­sil­i­co Med­i­cine has nabbed a new Big Phar­ma part­ner: Boehringer In­gel­heim.

The deal is with Boehringer’s Re­search Be­yond Bor­ders, an ini­tia­tive de­vot­ed to find­ing and part­ner­ing with new tech­nolo­gies, par­tic­u­lar­ly in Asia. It will give the Ger­man drug­mak­er ac­cess to a pair of In­sil­i­co plat­forms: their gen­er­a­tive AI soft­ware that dis­cov­ers new drug can­di­dates and their “Pan­domics” plat­form that pro­vides a host of bi­o­log­i­cal da­ta for any project. Fi­nan­cial terms were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER